Risk mitigation in psychedelic treatment

Screening & Eligibility

A structured pre-treatment review is not a formality. It is the point where medical history, psychiatric context, medications, consent, and practical support are considered together before a decision is documented.

Purpose of review

Eligibility is a documented reasoning process.

For people examining risk mitigation in psychedelic treatment, screening is best understood as a sequence of checks rather than a single pass-or-fail event. Trial protocols, product labeling, local regulation, and the intended setting can all shape what is reviewed and who must participate in the decision.

This guide sits within the site’s wider framework for risk mitigation in psychedelic treatment and focuses on the pre-treatment stage: gathering relevant information, recognizing factors that may require caution, and recording whether a decision is made, deferred, or referred.

The account should remain evidence-first. A broad discussion of psychedelic substances can be found in the overview of psychedelic drugs, but that background does not substitute for product-specific protocols or a professional assessment.

Assessment domains

Build the record before interpreting it.

Published studies commonly combine a medical history, psychiatric interview, medication review, substance-use discussion, physical risk screen, and practical assessment of support and follow-up.

Medical history

Record current and past conditions, procedures, allergies, pregnancy-related considerations where relevant, prior reactions to psychoactive substances, and the clinician or service responsible for ongoing care.

Medication and substance use

Medication reconciliation should identify prescribed drugs, over-the-counter products, supplements, recent changes, and timing considerations. Discussion of alcohol and other substance use should distinguish current patterns, withdrawal risk, and the reliability of a plan for the assessment period.

Physical risk and setting

Cardiovascular history, seizure history, vital-sign concerns, and capacity for acute escalation may all matter. The FDA drug-safety communications framework illustrates why risk information changes over time and should be checked against current official materials.

Practical workflow

Use instruments to support consistency, not to erase judgment.

Trials frequently use structured diagnostic interviews, symptom measures, medical questionnaires, medication logs, and vital-sign review. A protocol may specify thresholds or exclusions, but thresholds are not portable rules for every setting or person.

For example, screening may use validated measures for depressive symptoms, anxiety, suicidality, alcohol use, or substance use; a structured interview can clarify whether a history meets a protocol-defined exclusion. The appropriate tool, timing, and interpretation depend on the study, medicine, indication, and local governance.

Where facts are incomplete, rapidly changing, or inconsistent, a defensible workflow notes the uncertainty. That may mean pausing, seeking records, consulting an appropriate clinician, or referring rather than treating a checklist score as conclusive.

  1. 01
    Collect and reconcile Gather self-report, available records, medication and supplement information, relevant substance-use context, and a clear account of current care.
  2. 02
    Screen for protocol-defined concerns Apply the published or locally approved inclusion, exclusion, and monitoring requirements appropriate to the substance and setting.
  3. 03
    Clarify uncertainty Use structured instruments, collateral records where appropriate, and qualified review to resolve unclear psychiatric, cardiovascular, seizure, or medication issues.
  4. 04
    Document the decision path Record what was reviewed, what remains unknown, the basis for proceeding or deferring, and any referral or follow-up plan.

Consent and decision records

Consent is ongoing, specific, and understandable.

Informed consent should describe known risks, important uncertainties, alternatives, preparation expectations, possible acute responses, privacy boundaries, available support, and what follow-up may involve. It should also make clear that a person can raise questions or decline participation without the process becoming a sales exercise.

For context on the legal and ethical foundations of consent, the U.S. Department of Health and Human Services human-subject protections set out established requirements for research settings. Clinical and non-research contexts can differ, so current local requirements need separate review.

People looking for the broader scope of this independent resource can see how Mitigaine Risk Management frames its information. The goal here is not to decide eligibility remotely, but to make the screening questions and documentation logic legible.

A record should show not only the outcome, but what information supported it, what uncertainty remained, and why a pause or referral was considered when relevant.

Areas requiring judgment

Questions that should not be answered by a checkbox.

These concise answers reflect common protocol logic and the limits of general information. They are not clinical advice or universal eligibility criteria.

Why are psychosis and bipolar-spectrum histories considered during screening?

Published trial protocols often use exclusions or heightened review for personal histories of psychotic disorders, manic episodes, and sometimes certain family histories. These choices are risk-management measures rather than universal diagnostic rules. Interpretation of a history, current symptoms, and family context requires qualified clinical judgment.

Can a checklist determine eligibility?

No. Structured instruments can improve consistency and documentation, but they do not replace medical review, medication reconciliation, discussion of uncertainty, or a decision about whether assessment should be deferred or referred. A score or threshold only has meaning within the protocol that specifies it.

When should review be deferred or referred?

Deferral or referral may be considered when there is an unresolved medical issue, unclear medication interaction, acute psychiatric instability, possible withdrawal risk, an incomplete history, concern about cardiovascular or seizure risk, or uncertainty about the setting’s ability to respond. The reason for that step should be documented rather than treated as an unexplained exclusion.

What belongs in an informed-consent record?

A useful record documents the process: known and uncertain risks, alternatives, preparation expectations, privacy and support boundaries, acute escalation planning, post-session follow-up, participant questions, and the basis for the final decision. Consideration of ibogaine and brain-aging questions also warrants substance-specific review rather than assumptions transferred from a different protocol.

Keep the sequence visible

Clear records make risk discussions easier to examine.

Screening and eligibility are only one part of a wider safety pathway. Continue with the practical information on acute decision-making, monitoring, and escalation planning.

Explore dosing & acute safety